These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15562199

  • 1. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.
    Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, DeFronzo RA.
    Diabetes Care; 2004 Dec; 27(12):2868-73. PubMed ID: 15562199
    [Abstract] [Full Text] [Related]

  • 2. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
    Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.
    Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
    [Abstract] [Full Text] [Related]

  • 3. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.
    Clement S, Still JG, Kosutic G, McAllister RG.
    Diabetes Technol Ther; 2002 Feb; 4(4):459-66. PubMed ID: 12396740
    [Abstract] [Full Text] [Related]

  • 4. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial.
    Clement S, Dandona P, Still JG, Kosutic G.
    Metabolism; 2004 Jan; 53(1):54-8. PubMed ID: 14681842
    [Abstract] [Full Text] [Related]

  • 5. Simulated first-phase insulin release using Humulin or insulin analog HIM2 is associated with prolonged improvement in postprandial glycemia.
    DiCostanzo CA, Moore MC, Lautz M, Scott M, Farmer B, Everett CA, Still JG, Higgins A, Cherrington AD.
    Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E46-52. PubMed ID: 15713685
    [Abstract] [Full Text] [Related]

  • 6. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
    Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H.
    Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
    [Abstract] [Full Text] [Related]

  • 7. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
    Horvath K, Bock G, Regittnig W, Bodenlenz M, Wutte A, Plank J, Magnes C, Sinner F, Fürst-Recktenwald S, Theobald K, Pieber TR.
    Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
    [Abstract] [Full Text] [Related]

  • 8. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
    Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H.
    Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
    Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H.
    Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
    [Abstract] [Full Text] [Related]

  • 10. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB.
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [Abstract] [Full Text] [Related]

  • 11. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.
    Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS, Heinemann L, Batycky RP, Muchmore DB.
    Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270
    [Abstract] [Full Text] [Related]

  • 12. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
    Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S.
    Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
    [Abstract] [Full Text] [Related]

  • 13. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I.
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [Abstract] [Full Text] [Related]

  • 14. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [Abstract] [Full Text] [Related]

  • 15. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
    Joseph SE, Korzon-Burakowska A, Woodworth JR, Evans M, Hopkins D, Janes JM, Amiel SA.
    Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
    [Abstract] [Full Text] [Related]

  • 16. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB, Home PD.
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR.
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [Abstract] [Full Text] [Related]

  • 18. 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study.
    Iozzo P, Gastaldelli A, Järvisalo MJ, Kiss J, Borra R, Buzzigoli E, Viljanen A, Naum G, Viljanen T, Oikonen V, Knuuti J, Savunen T, Salvadori PA, Ferrannini E, Nuutila P.
    J Nucl Med; 2006 Jun; 47(6):1016-22. PubMed ID: 16741312
    [Abstract] [Full Text] [Related]

  • 19. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB, Mallias J, Home PD.
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [Abstract] [Full Text] [Related]

  • 20. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
    Henriksen JE, Levin K, Thye-Rønn P, Alford F, Hother-Nielsen O, Holst JJ, Beck-Nielsen H.
    Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.